Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial
(2024)
Journal Article
McIlroy, G., Lax, S., Gaskell, C., Jackson, A., Rhodes, M., Seale, T., Fox, Hopkins, L., Okosun, J., Barrington, S. F., Ringshausen, I., Ramsay, A. G., Calaminici, Linton, K., & Bishton, M. (2024). Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial. BMC Cancer, 24, Article 370. https://doi.org/10.1186/s12885-024-12112-0
Background
Relapsed or refractory follicular lymphoma (rrFL) is an incurable disease associated with shorter remissions and survival after each line of standard therapy. Many promising novel, chemotherapy-free therapies are in development, but few a...
Read More about Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial.